Polaris Partners — 2025 Investments

Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy.

BiotechHealthtechLongevityCambridge, US

YKYing Kai Chan(Co-founder & CEO)inAndrew Dick(Director, Promoter)

BoardKhoo Shih(Director)

Board seatACAlexandra Cantley· per SEC Form D · $15.7M raise · filed Aug 2025

Co-investorsCLClavystBioLOLong GameZAZAKA VC

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDWDmitri Wiederschain(Executive Officer)in

BoardSakae Asanuma(Director)inBMBriggs Morrison(Executive Officer, Director, Promoter)inIMIrena Melnikova(Director)in

Board seatACAlexandra Cantley· per SEC Form D · $80M raise · filed Sep 2025

Co-investorsLILifelinkMPMPM BioImpactPFPfizer Venture InvestmentsBIBiotechnology Value FundMIMirae Asset Venture InvestmentPFPfizer Ventures+1 more

Nomad Health operates an online marketplace that matches travel nurses and allied health clinicians with temporary healthcare jobs based on their profiles and preferences.

Digital HealthHealthtechMarketplacesNew York, US

Maxwell Laurans(Director)ANAlexi Nazem(Co-Founder & Board Member)inAlexander Nazem, MD(Founder)Max Laurens, MD(Founder)RGRyan Grant, MD(Founder)inJLJustin Lambert(CEO)in

Board seatBCBrian Chee· per SEC Form D

Co-investorsALAlleyCorpFIFirst Round CapitalICIcon VenturesRRRRE Ventures.4.406 VenturesADAdams Street Partners+1 more

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

KEKevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)KRKasper Roet(Founder, Chief Executive Officer)inSVShafique Virani(Executive Officer)inJBJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Board seatASAmy Schulman· per SEC Form D · $24.9M raise · filed Sep 2025

Co-investorsALALS Investment FundDODolby Family VenturesDRDroia VenturesINInkefMCMC Healthcare VenturesMIMission Biocapital+8 more

FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.

Digital HealthHardwareMedical DevicesDublin, IE

Co-investorsANAndera PartnersGIGimvIRIreland Strategic Investment FundLILightstone VenturesLOLongitude CapitalNENew Enterprise Associates (NEA)+5 more

Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.

AI & Machine LearningBiotechDeep TechWatertown, US

VKVictor Kotelianski(Founder)DADaniel Anderson(Founder and Director)RLRobert Langer(Founder)MZMarino Zerial(Founder)BPBrad Pentelute(Founder)ANAmir Nashat, ScD(Founder, Director and CEO)

Co-investorsLELeaps by BayerBEBessemer Venture PartnersSASafar PartnersVIVida Ventures

Zag Bio develops thymus-targeted bifunctional antibodies designed to induce central tolerance for treating autoimmune diseases.

BiotechDeep TechHealthtechMedical DevicesCambridge, US

Alan Crane(Founder)Diane Mathis(Founder)Joanne Lim(Co-founder)Dr. Diane Mathis(Founder)Jo Viney(Founder)John Kulman(Founder)

Co-investorsLILightspeed Venture PartnersMIMission BiocapitalPEPear VCSASanofi VenturesTHThe Engine Ventures